セロクエル２５ｍｇ錠
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB01224 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 35 |
| 日本商品名（例） | クエチアピンフマル酸塩１２．５ｍｇ錠, クエチアピンフマル酸塩２５ｍｇ錠, クエチアピン細粒１０％「アメル」 |
承認適応症（KEGG）
統合失調症、双極性障害におけるうつ症状
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | major affective disorder | 99% | DL |
| 2 | manic bipolar affective disorder | 99% | DL |
| 3 | schizophrenia | 99% | DL |
| 4 | bipolar disorder | 99% | DL |
| 5 | retinal dystrophy with or without extraocular anomalies | 99% | DL |
| 6 | congenital disorder of glycosylation with defective fucosylation | 99% | DL |
| 7 | hydranencephaly (disease) | 99% | DL |
| 8 | distal 17p13.3 microdeletion syndrome | 99% | DL |
| 9 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99% | DL |
| 10 | myopia X-linked | 99% | DL |
| 11 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99% | DL |
| 12 | trichotillomania | 99% | DL |
| 13 | syndromic myopia | 99% | DL |
| 14 | myopia 26, X-linked, female-limited | 99% | DL |
| 15 | atypical glycine encephalopathy | 99% | DL |
| 16 | Malan overgrowth syndrome | 99% | DL |
| 17 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | 99% | DL |
| 18 | Tourette syndrome | 98% | DL |
| 19 | anxiety disorder | 98% | DL |
| 20 | benign paroxysmal torticollis of infancy | 97% | DL |
| 21 | agoraphobia | 97% | DL |
| 22 | schizophreniform disorder | 97% | DL |
| 23 | Phelan-McDermid syndrome | 96% | DL |
| 24 | dysthymic disorder | 95% | DL |
| 25 | attention deficit-hyperactivity disorder | 95% | DL |
| 26 | autism susceptibility 1 | 94% | DL |
| 27 | gaze palsy, familial horizontal, with progressive scoliosis | 94% | DL |
| 28 | striatal degeneration, autosomal dominant | 94% | DL |
| 29 | autism spectrum disorder | 93% | DL |
| 30 | faciodigitogenital syndrome | 93% | DL |
| 31 | asperger syndrome, susceptibility to | 92% | DL |
| 32 | chondromyxoid fibroma | 92% | DL |
| 33 | childhood apraxia of speech | 92% | DL |
| 34 | amelocerebrohypohidrotic syndrome | 91% | DL |
| 35 | attention deficit hyperactivity disorder, inattentive type | 91% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。